Clinical Trial Update: An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia [Phase 3]

View source ↗

Summary

An open-label extension of a Phase 3 trial assessing the long-term safety and efficacy of mipomersen in patients with familial hypercholesterolemia or severe hy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Hypercholesterolemia
• Hypercholesterolemia

Drugs mentioned

• Mipomersen (mipomersen)

Snippet

Sponsor: Kastle Therapeutics, LLC | Conditions: Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant | Phase 3 | Status: COMPLETED | Results posted: 2015-12-21